Crohn's Disease

Phase 2 data support the safety and efficacy of mirikizumab in patients with Crohn’s disease, according to results presented at UEG Week.

In this exclusive video, William J. Sandborn, MD, discusses interim results from the phase 2 GALAXI 1 study of Tremfya in patients with Crohn’s disease.

In this exclusive video from UEG Week Virtual, William J. Sandborn, MD, from the University of California, San Diego, discusses the final results from the IM-UNITI long-term extension trial of Stelara in patients with Crohn’s disease.

The interim analysis of subcutaneous Entyvio demonstrates the treatment is safe and effective for long-term maintenance of ulcerative colitis, according to results presented at UEG Week.

Patients with Crohn’s disease improved sleep disturbance with a stepped-care approach that included brief behavioral therapy, according to study results.

Risk for developing inflammatory bowel disease was increased among first-degree relatives of individuals who already had the disease, according to study results.

Treatment of psoriatic conditions or Crohn’s disease with ustekinumab was associated with severe cardiovascular events in certain high-risk patients, according to a study.

After surgery for Crohn’s disease, anti-tumor necrosis factor therapy was efficacious for preventing endoscopic recurrence without an increase in the incidence of adverse events, according to study results.

The Cleveland Clinic has appointed colorectal surgeon Conor Delaney, MD, PhD, as the new CEO and president of the institution’s Florida region. It was the top story in gastroenterology last week.

Patient preference favoring treatment discontinuation was improved during treatment with Entyvio or Stelara compared with anti-TNF therapy in patients with inflammatory bowel disease, according to study results.